NCT04055818View on ClinicalTrials.gov

A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease

PHASE1RecruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

January 24, 2020

Primary Completion Date

October 30, 2026

Study Completion Date

April 30, 2027

Conditions

Sickle Cell Disease

Interventions

DRUG

Nicotinamide

Oral nicotinamide (Vitamin B3) alone compared to THU Decitabine combination

Trial Locations (1)

60612

RECRUITING

University of Illinois at Chicago College of Medicine, Chicago

Sponsors

Lead Sponsor

EpiDestiny, Inc.

All Listed Sponsors

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

EpiDestiny, Inc.

INDUSTRY

NCT04055818 - A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease | Biotech Hunter | Biotech Hunter